1. Home
  2. TRDA vs HERE Comparison

TRDA vs HERE Comparison

Compare TRDA & HERE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRDA
  • HERE
  • Stock Information
  • Founded
  • TRDA 2016
  • HERE 2019
  • Country
  • TRDA United States
  • HERE China
  • Employees
  • TRDA N/A
  • HERE N/A
  • Industry
  • TRDA Biotechnology: Pharmaceutical Preparations
  • HERE Other Consumer Services
  • Sector
  • TRDA Health Care
  • HERE Real Estate
  • Exchange
  • TRDA Nasdaq
  • HERE Nasdaq
  • Market Cap
  • TRDA 350.5M
  • HERE 296.4M
  • IPO Year
  • TRDA 2021
  • HERE 2023
  • Fundamental
  • Price
  • TRDA $9.92
  • HERE $5.13
  • Analyst Decision
  • TRDA Strong Buy
  • HERE
  • Analyst Count
  • TRDA 2
  • HERE 0
  • Target Price
  • TRDA $24.50
  • HERE N/A
  • AVG Volume (30 Days)
  • TRDA 293.9K
  • HERE 301.8K
  • Earning Date
  • TRDA 11-06-2025
  • HERE 11-28-2025
  • Dividend Yield
  • TRDA N/A
  • HERE N/A
  • EPS Growth
  • TRDA N/A
  • HERE N/A
  • EPS
  • TRDA N/A
  • HERE 0.91
  • Revenue
  • TRDA $61,520,000.00
  • HERE $380,467,350.00
  • Revenue This Year
  • TRDA N/A
  • HERE N/A
  • Revenue Next Year
  • TRDA N/A
  • HERE $14.46
  • P/E Ratio
  • TRDA N/A
  • HERE $5.62
  • Revenue Growth
  • TRDA N/A
  • HERE N/A
  • 52 Week Low
  • TRDA $4.93
  • HERE $1.60
  • 52 Week High
  • TRDA $21.79
  • HERE $15.64
  • Technical
  • Relative Strength Index (RSI)
  • TRDA 76.59
  • HERE N/A
  • Support Level
  • TRDA $8.17
  • HERE N/A
  • Resistance Level
  • TRDA $9.12
  • HERE N/A
  • Average True Range (ATR)
  • TRDA 0.72
  • HERE 0.00
  • MACD
  • TRDA 0.20
  • HERE 0.00
  • Stochastic Oscillator
  • TRDA 87.16
  • HERE 0.00

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: